Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

Subcutaneous human IgG (SCIG) therapy in primary immunodeficiency (PID) offers sustained IgG levels throughout the dosing cycle and fewer adverse events (AEs) compared to intravenous immunoglobulin (IVIG). A phase I study showed good local tolerability of IgPro20, a new 20% liquid SCIG stabilized wi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Hagan, John B., Fasano, Mary B., Spector, Sheldon, Wasserman, Richard L., Melamed, Isaac, Rojavin, Mikhail A., Zenker, Othmar, Orange, Jordan S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer US 2010
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935975/
https://ncbi.nlm.nih.gov/pubmed/20454851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-010-9423-4
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg